구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp) Genmab / AbbVie·CD20 × CD3 57 trials·t½ ~3 weeks at steady state | doxorubicin hydrochloride (doxorubicin hydrochloride) Prescient Therapeutics, Ltd.·Lymphoma 218 trials·t½ 78.4 days | ||
|---|---|---|---|---|
Overview Program | Columvi (glofitamab) | Epkinly (epcoritamab) | Obinutuzumab | doxorubicin hydrochloride |
Overview Company | Roche / Genentech | Genmab / AbbVie | Roche / Genentech | Prescient Therapeutics, Ltd. |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CD20 × CD3 | CD20 × CD3 | B-cell Lymphoma | Lymphoma |
Overview Indication | Relapsed or refractory diffuse large B-cell lymphoma | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma | Breast Adenocarcinoma; Metastatic Breast Carcinoma | Breast Neoplasms; Breast Cancer |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS. | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. | novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr | — |
Positioning Known limitation | CD20 loss after prior anti-CD20 therapy and T-cell exhaustion. | CD20 antigen loss and exhausted effector T cells after multiple prior lines. | resistance to treatment | — |
Positioning Development positioning | Competes with Epkinly on schedule and route; fixed duration is its main claim. | Main SC alternative to Columvi, with continuous rather than fixed duration. | — | — |
MoA Mechanism | Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis. | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. | targets type I interferon signaling | target multiple pathway |
MoA Biomarker | CD20 expression; ctDNA clearance investigational. | CD20 expression; ctDNA MRD investigational. | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | HER2-positive breast cancer models, including cell lines (CD44 high |
PK/PD Half-life | ~1–2 weeks | ~3 weeks at steady state | — | 78.4 days |
PK/PD Species | Cynomolgus monkey, B-cell depletion, cytokine profile, PET-CR | Cynomolgus monkey, Peripheral B-cell depletion, cytokine kinetics, PET response | Cynomolgus monkey, Macaque, Mouse | Mouse |
PK/PD Animal (cat.) | Human, NHP | Human, NHP, In vitro | Mouse, NHP, Monkey | Mouse, In vitro |
PK/PD Experiment | Pharmacodynamic | pharmacokinetic | Pharmacodynamic | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse | Cynomolgus monkey | Cynomolgus monkey, Macaque, Mouse | Mouse |
Toxicology Animal (cat.) | — | — | Mouse, NHP, Monkey | Mouse, In vitro |
Toxicology Major finding | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | thrombocytopenia or organ dysfunction, were documented | Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer.. Combination chemotherapy is often limited by the distinct physicochemical properties and intracellular behaviors of individual drugs. This limitation leads to poorly coordinated delivery in tumor tissues. In this study… |
Toxicology CRS | CRS ~63%, grade ≥3 ~4% | CRS ~50%, grade ≥3 ~2.5% | Reported | — |
Clinical Safety signal | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | thrombocytopenia or organ dysfunction, were documented | Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer.. Combination chemotherapy is often limited by the distinct physicochemical properties and intracellular behaviors of individual drugs. This limitation leads to poorly coordinated delivery in tumor tissues. In this study… |
Clinical Selected reported efficacy | ORR 35.3% | ORR 61% | ORR 100% | ORR 95% |
Clinical Reported ORR | 35.3% | 61% (DLBCL) | 100.0% | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT04313608 | EPCORE NHL-1 (NCT03625037) | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT03677141 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04313608 | NCT03625037 | NCT02611323 | NCT03677141 |
Preclinical Animal (cat.) | NHP | Human, NHP, Monkey, In vitro | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp) Genmab / AbbVie·CD20 × CD3 57 trials·t½ ~3 weeks at steady state | doxorubicin hydrochloride (doxorubicin hydrochloride) Prescient Therapeutics, Ltd.·Lymphoma 218 trials·t½ 78.4 days | ||
|---|---|---|---|---|
Overview Program | Columvi (glofitamab) | Epkinly (epcoritamab) | Obinutuzumab | doxorubicin hydrochloride |
Overview Company | Roche / Genentech | Genmab / AbbVie | Roche / Genentech | Prescient Therapeutics, Ltd. |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CD20 × CD3 | CD20 × CD3 | B-cell Lymphoma | Lymphoma |
Overview Indication | Relapsed or refractory diffuse large B-cell lymphoma | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma | Breast Adenocarcinoma; Metastatic Breast Carcinoma | Breast Neoplasms; Breast Cancer |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS. | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. | novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr | — |
Positioning Known limitation | CD20 loss after prior anti-CD20 therapy and T-cell exhaustion. | CD20 antigen loss and exhausted effector T cells after multiple prior lines. | resistance to treatment | — |
Positioning Development positioning | Competes with Epkinly on schedule and route; fixed duration is its main claim. | Main SC alternative to Columvi, with continuous rather than fixed duration. | — | — |
MoA Mechanism | Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis. | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. | targets type I interferon signaling | target multiple pathway |
MoA Biomarker | CD20 expression; ctDNA clearance investigational. | CD20 expression; ctDNA MRD investigational. | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | HER2-positive breast cancer models, including cell lines (CD44 high |
PK/PD Half-life | ~1–2 weeks | ~3 weeks at steady state | — | 78.4 days |
PK/PD Species | Cynomolgus monkey, B-cell depletion, cytokine profile, PET-CR | Cynomolgus monkey, Peripheral B-cell depletion, cytokine kinetics, PET response | Cynomolgus monkey, Macaque, Mouse | Mouse |
PK/PD Animal (cat.) | Human, NHP | Human, NHP, In vitro | Mouse, NHP, Monkey | Mouse, In vitro |
PK/PD Experiment | Pharmacodynamic | pharmacokinetic | Pharmacodynamic | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse | Cynomolgus monkey | Cynomolgus monkey, Macaque, Mouse | Mouse |
Toxicology Animal (cat.) | — | — | Mouse, NHP, Monkey | Mouse, In vitro |
Toxicology Major finding | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | thrombocytopenia or organ dysfunction, were documented | Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer.. Combination chemotherapy is often limited by the distinct physicochemical properties and intracellular behaviors of individual drugs. This limitation leads to poorly coordinated delivery in tumor tissues. In this study… |
Toxicology CRS | CRS ~63%, grade ≥3 ~4% | CRS ~50%, grade ≥3 ~2.5% | Reported | — |
Clinical Safety signal | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | thrombocytopenia or organ dysfunction, were documented | Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer.. Combination chemotherapy is often limited by the distinct physicochemical properties and intracellular behaviors of individual drugs. This limitation leads to poorly coordinated delivery in tumor tissues. In this study… |
Clinical Selected reported efficacy | ORR 35.3% | ORR 61% | ORR 100% | ORR 95% |
Clinical Reported ORR | 35.3% | 61% (DLBCL) | 100.0% | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT04313608 | EPCORE NHL-1 (NCT03625037) | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT03677141 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04313608 | NCT03625037 | NCT02611323 | NCT03677141 |
Preclinical Animal (cat.) | NHP | Human, NHP, Monkey, In vitro | — | — |
추천 비교
추천 비교